Home

Converge Settle meghatalmazás national geographic astrazeneca Járda erény fájl

AstraZeneca weighs spinning out COVID-19 products into separate company:  Bloomberg | Fierce Pharma
AstraZeneca weighs spinning out COVID-19 products into separate company: Bloomberg | Fierce Pharma

Advancing data and artificial intelligence
Advancing data and artificial intelligence

AstraZeneca nets $396M down payment from EU for 300M-plus COVID vaccines |  Fierce Pharma
AstraZeneca nets $396M down payment from EU for 300M-plus COVID vaccines | Fierce Pharma

Pakistan allows AstraZeneca shot for under 40s to help its expatriates |  Reuters
Pakistan allows AstraZeneca shot for under 40s to help its expatriates | Reuters

Keith Burns - Director of U.S. Tax Operations - AstraZeneca | LinkedIn
Keith Burns - Director of U.S. Tax Operations - AstraZeneca | LinkedIn

Advancing data and artificial intelligence
Advancing data and artificial intelligence

Rick R. Suarez
Rick R. Suarez

AstraZeneca's vaccine has 76 percent efficacy—slightly lower than the  interim results announced Monday
AstraZeneca's vaccine has 76 percent efficacy—slightly lower than the interim results announced Monday

Personified
Personified

Poorer countries hit with higher price tag for Oxford/AstraZeneca vaccine –  POLITICO
Poorer countries hit with higher price tag for Oxford/AstraZeneca vaccine – POLITICO

Vaccines | Free Full-Text | Report of Adverse Effects Following  Population-Wide COVID-19 Vaccination: A Comparative Study between Six  Different Vaccines in Baja-California, Mexico
Vaccines | Free Full-Text | Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico

US finds COVID-19 Vaccine AstraZeneca safe and effective
US finds COVID-19 Vaccine AstraZeneca safe and effective

AstraZeneca US
AstraZeneca US

AstraZeneca CEO Soriot scored $18.5M pay package amid oncology, rare  disease rebrand | Fierce Pharma
AstraZeneca CEO Soriot scored $18.5M pay package amid oncology, rare disease rebrand | Fierce Pharma

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine |  NEJM
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | NEJM

Women's History Month: Celebrating Pioneers and Future Trailblazers
Women's History Month: Celebrating Pioneers and Future Trailblazers

Frontiers | Extension and Severity of Self-Reported Side Effects of Seven  COVID-19 Vaccines in Mexican Population
Frontiers | Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

Vaccines | Free Full-Text | Prospective Evaluation of Side-Effects  Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among  Healthcare Workers in Saudi Arabia
Vaccines | Free Full-Text | Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia

AstraZeneca in United States
AstraZeneca in United States